These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35931648)

  • 1. Familial hypobetalipoproteinemia caused by homozygous loss-of-function mutations in PCSK9: A case report.
    Kudo T; Sasaki K; Tada H
    J Clin Lipidol; 2022; 16(5):596-600. PubMed ID: 35931648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Healthy Family of Familial Hypobetalipoproteinemia Caused by a Protein-truncating Variant in the PCSK9 Gene.
    Tada H; Okada H; Nomura A; Nohara A; Takamura M; Kawashiri MA
    Intern Med; 2020; 59(6):783-787. PubMed ID: 32173689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia.
    Cariou B; Ouguerram K; Zaïr Y; Guerois R; Langhi C; Kourimate S; Benoit I; Le May C; Gayet C; Belabbas K; Dufernez F; Chétiveaux M; Tarugi P; Krempf M; Benlian P; Costet P
    Arterioscler Thromb Vasc Biol; 2009 Dec; 29(12):2191-7. PubMed ID: 19762784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The c.43_44insCTG variation in PCSK9 is associated with low plasma LDL-cholesterol in a Caucasian population.
    Yue P; Averna M; Lin X; Schonfeld G
    Hum Mutat; 2006 May; 27(5):460-6. PubMed ID: 16619215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol.
    Fasano T; Cefalù AB; Di Leo E; Noto D; Pollaccia D; Bocchi L; Valenti V; Bonardi R; Guardamagna O; Averna M; Tarugi P
    Arterioscler Thromb Vasc Biol; 2007 Mar; 27(3):677-81. PubMed ID: 17170371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel mutations in SAR1B and MTTP genes in Tunisian children with chylomicron retention disease and abetalipoproteinemia.
    Magnolo L; Najah M; Fancello T; Di Leo E; Pinotti E; Brini I; Gueddiche NM; Calandra S; Slimene NM; Tarugi P
    Gene; 2013 Jan; 512(1):28-34. PubMed ID: 23043934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels.
    Lipari MT; Li W; Moran P; Kong-Beltran M; Sai T; Lai J; Lin SJ; Kolumam G; Zavala-Solorio J; Izrael-Tomasevic A; Arnott D; Wang J; Peterson AS; Kirchhofer D
    J Biol Chem; 2012 Dec; 287(52):43482-91. PubMed ID: 23135270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Removal of plasma mature and furin-cleaved proprotein convertase subtilisin/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9.
    Hori M; Ishihara M; Yuasa Y; Makino H; Yanagi K; Tamanaha T; Kishimoto I; Kujiraoka T; Hattori H; Harada-Shiba M
    J Clin Endocrinol Metab; 2015 Jan; 100(1):E41-9. PubMed ID: 25313916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypobetalipoproteinemia and abetalipoproteinemia.
    Welty FK
    Curr Opin Lipidol; 2014 Jun; 25(3):161-8. PubMed ID: 24751931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urine-sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia.
    Si-Tayeb K; Idriss S; Champon B; Caillaud A; Pichelin M; Arnaud L; Lemarchand P; Le May C; Zibara K; Cariou B
    Dis Model Mech; 2016 Jan; 9(1):81-90. PubMed ID: 26586530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Familial hypobetalipoproteinemia in a hospital survey: genetics, metabolism and non-alcoholic fatty liver disease.
    Gutiérrez-Cirlos C; Ordóñez-Sánchez ML; Tusié-Luna MT; Patterson BW; Schonfeld G; Aguilar-Salinas CA
    Ann Hepatol; 2011; 10(2):155-64. PubMed ID: 21502677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of novel APOB mutations by targeted next-generation sequencing for the molecular diagnosis of familial hypobetalipoproteinemia.
    Rimbert A; Pichelin M; Lecointe S; Marrec M; Le Scouarnec S; Barrak E; Croyal M; Krempf M; Le Marec H; Redon R; Schott JJ; Magré J; Cariou B
    Atherosclerosis; 2016 Jul; 250():52-6. PubMed ID: 27179706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study.
    Simonen P; Stenman UH; Gylling H
    Clin Sci (Lond); 2015 Sep; 129(5):439-46. PubMed ID: 25857271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
    Bergeron N; Phan BA; Ding Y; Fong A; Krauss RM
    Circulation; 2015 Oct; 132(17):1648-66. PubMed ID: 26503748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PCSK9 gene mutations and low-density lipoprotein cholesterol.
    Wu NQ; Li JJ
    Clin Chim Acta; 2014 Apr; 431():148-53. PubMed ID: 24518357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypobetalipoproteinemia: genetics, biochemistry, and clinical spectrum.
    Tarugi P; Averna M
    Adv Clin Chem; 2011; 54():81-107. PubMed ID: 21874758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
    Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
    Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of mutations in LDLR and PCSK9 genes on phenotypic variability in Tunisian familial hypercholesterolemia patients.
    Slimani A; Jelassi A; Jguirim I; Najah M; Rebhi L; Omezzine A; Maatouk F; Hamda KB; Kacem M; Rabès JP; Abifadel M; Boileau C; Rouis M; Slimane MN; Varret M
    Atherosclerosis; 2012 May; 222(1):158-66. PubMed ID: 22417841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease.
    Abifadel M; Rabès JP; Devillers M; Munnich A; Erlich D; Junien C; Varret M; Boileau C
    Hum Mutat; 2009 Apr; 30(4):520-9. PubMed ID: 19191301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.